ResultsĪs of 30 April 2020, 57 pts from dose escalation and dose expansion were treated at the 5.6 mg/kg dose, and 56 pts were evaluable for response.
Patritumab deruxtecan was administered IV Q3W. Primary objective is assessment of activity by confirmed ORR (blinded independent central review, BICR) secondary objectives include evaluation of safety. The dose expansion part enrolled pts with EGFRm NSCLC with prior EGFR TKI and platinum-based chemotherapy. The dose escalation part was presented previously. We report safety and activity in such pts treated in a phase I study (NCT03260491) with patritumab deruxtecan, a HER3 directed antibody drug conjugate, at the 5.6 mg/kg recommended dose for expansion.
There are few treatment options for pts with advanced EGFRm NSCLC after failure of EGFR TKI and platinum-based chemotherapy. 15 Medical Oncology, Dana Farber Cancer Institute, 02215 - Boston/US.13 Clinical Biomarkers, Daiichi Sankyo Co.12 Global Oncology, Daiichi Sankyo Co.11 Oncology, National Taiwan University Hospital, 100 - Taipei/TW.10 Internal Medicine, National Cheng Kung University Hospital, 704 - Tainan/TW.9 Hematology And Medical Oncology, Emory University Hospital, 30322 - Atlanta/US.8 Thoracic Surgical Oncology Department, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP.7 Thoracic Oncology, Shizuoka Cancer Center, 411-0934 - Sunto-gun/JP.6 Medical Oncology, City of Hope, 91010 - Duarte/US.
0 kommentar(er)
